Physician profile
Regan A Schwartz
NPI 1366430704
$5,512.96
in general payments reported to CMS, 2019-2025
17 companies · $966 in 2025
The $966 reported for 2025 was more than what 95% of Emergency Medical Services providers received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $222 · 2021: $244 · 2022: $1,088 · 2023: $1,254 · 2024: $1,051 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $979.94 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $959.51 | 2021-2025 | Fasenra, Andexxa, Airsupra |
| Abbvie INC. | $589.31 | 2022-2024 | Dalvance |
| Inari Medical, INC. | $402.77 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Grifols USA, LLC | $398.11 | 2022-2023 | Hyperrab |
| Csl Behring | $345.38 | 2022-2024 | Kcentra |
| Allergan, INC. | $340.24 | 2019-2020 | |
| Penumbra, INC. | $253.82 | 2025 | Indigo System |
| Atricure, INC. | $250.08 | 2025 | Synergy Ablation System |
| Genentech USA, INC. | $247.51 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $215.93 | 2019-2023 | Eliquis |
| Glaxosmithkline, LLC. | $118.61 | 2024 | Nucala |
| Alexion Pharmaceuticals, INC. | $112.47 | 2024 | |
| Stryker Corporation | $110.31 | 2025 | Flowtriever |
| Gilead Sciences, INC. | $85.05 | 2023 | Veklury |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $58.09 | 2024 | |
| Mindray Ds USA, INC. | $45.83 | 2023 | Te X, Te7 Max |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regan Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.